The rationale for xanomeline+trospium (Cobenfy™), approved for the treatment of schizophrenia

In September 2024, the United States Food and Drug Administration (FDA) approved the combination of two drugs—xanomeline and trospium—in the same capsule (under the brand name Cobenfy™) for the treatment of schizophrenia in adults. The combination was previously known as KarXT. This combination medication is receiving a lot of attention because, unlike all previous medications…